Trial Profile
Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Netazepide (Primary)
- Indications Barrett's oesophagus; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Trio Medicines
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 08 Dec 2017 Status changed from recruiting to active, no longer recruiting.